Previous 10 |
home / stock / orinf / orinf news
Orion Oyj (ORINF) Q2 2022 Results Conference Call July 15, 2022 6:30 AM ET Company Participants Tuukka Hirvonen - Head, IR Timo Lappalainen - CEO Jari Karlson - CFO Conference Call Participants Jo Walton - Credit Suisse Sami Sarkamies - Danske Ban...
The following slide deck was published by Orion Oyj in conjunction with their 2022 Q2 earnings call. For further details see: Orion Oyj 2022 Q2 - Results - Earnings Call Presentation
Orion Oyj (ORINF) Q1 2022 Results Conference Call April 28, 2022 06:30 AM ET Company Participants Tuukka Hirvonen - Head, IR Timo Lappalainen - CEO Jari Karlson - CFO Conference Call Participants Harry Sephton - Credit Suisse Sami Sarkamies - Danske Bank Presentation Tuukka Hirvonen Good afte...
Orion Oyj press release (OTCPK:ORINF): Q1 GAAP EPS of €0.41. Revenue of €270.6M (+0.7% Y/Y). Operating profit was €71M Profit before taxes was €72M Equity ratio was 53%. Return on capital employed before taxes was 36%. Return on equity after tax...
My portfolio crossed the mark where I could lock in capital gains, switch decidedly to income stocks and retire today. That is, if these income stocks yield at least some 4.5%. Yield is easy to find, but can it be relied on? For further details see: High Yield And Low Co...
AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...
News, Short Squeeze, Breakout and More Instantly...
Orion Corp New B Shs Company Name:
ORINF Stock Symbol:
OTCMKTS Market:
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024 Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety...
ORION CORPORATION PRESS RELEASE 8 JANUARY 2024 at 09.00 EET Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs Orion Corporation and Glykos Finland Oy announced today that they have entered into a research collaborat...
ORION CORPORATION PRESS RELEASE 05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer OMAHA1 and OMAHA2a are the first Phase 3 trials to be initiated for...